Interferon Type I

Name
Interferon Type I
Accession Number
DBCAT000077
Description

Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA).

Drugs
DrugDrug Description
Peginterferon alfa-2aA modified form of recombinant human interferon used to stimulate the innate antiviral response in the treatment of hepatitis B and C viruses.
Interferon alfa-n1A purified form of human interferon used to stimulate the innate antiviral response in the treatment of genital warts due to human papilloma virus.
Interferon alfa-n3A purified form of human interferon used to stimulate the innate antiviral response in the treatment of genital warts due to human papilloma virus.
Peginterferon alfa-2bA purified form of human interferon used to stimulate the innate antiviral response in the treatment of hepatitis B and C, genital warts, and some cancers.
Interferon beta-1aA form of recombinant human interferon used to slow disease progression and reduce the frequency of clinical symptoms in patients who have relapsing multiple sclerosis.
Interferon beta-1bA form of recombinant human interferon used to slow the progression of relapsing multiple sclerosis and to reduce the frequency of clinical symptoms.
Interferon alfacon-1A recombinant interferon similar the interferon alfa subtype which is used to treat hepatitis C infections.
Interferon alfaInvestigated for use/treatment in hepatitis (viral, C), leukemia (lymphoid), leukemia (myeloid), leukemia (unspecified), and melanoma.
Albinterferon Alfa-2BInvestigated for use/treatment in hepatitis (viral, C).
Peginterferon beta-1aAn interferon beta used to treat relapsing forms of multiple sclerosis.
Human interferon betaA polypeptide drug used in the treatment of relapsing forms of Multiple Sclerosis (MS).
Interferon alfa-2cInterferon alfa-2c is under investigation in clinical trial NCT00485563 (A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma).
Drugs & Drug Targets
DrugTargetType
Peginterferon alfa-2aInterferon alpha/beta receptor 2target
Peginterferon alfa-2aInterferon alpha/beta receptor 1target
Peginterferon alfa-2aCytochrome P450 1A2enzyme
Interferon alfa-n1Interferon alpha/beta receptor 2target
Interferon alfa-n1Interferon alpha/beta receptor 1target
Interferon alfa-n1Cytochrome P450 1A2enzyme
Interferon alfa-n3Interferon alpha/beta receptor 1target
Interferon alfa-n3Interferon alpha/beta receptor 2target
Interferon alfa-n3Cytochrome P450 1A2enzyme
Peginterferon alfa-2bInterferon alpha/beta receptor 1target
Peginterferon alfa-2bInterferon alpha/beta receptor 2target
Peginterferon alfa-2bCytochrome P450 1A2enzyme
Peginterferon alfa-2bCytochrome P450 2D6enzyme
Peginterferon alfa-2bCytochrome P450 2C9enzyme
Interferon beta-1aInterferon alpha/beta receptor 1target
Interferon beta-1aInterferon alpha/beta receptor 2target
Interferon beta-1aCytochrome P450 1A2enzyme
Interferon beta-1bInterferon alpha/beta receptor 1target
Interferon beta-1bInterferon alpha/beta receptor 2target
Interferon beta-1bCytochrome P450 1A2enzyme
Interferon alfacon-1Interferon alpha/beta receptor 1target
Interferon alfacon-1Interferon alpha/beta receptor 2target
Interferon alfacon-1Cytochrome P450 1A2enzyme
Interferon alfaInterferon alpha/beta receptor 1target
Interferon alfaCytochrome P450 1A2enzyme
Albinterferon Alfa-2BCytochrome P450 1A2enzyme
Peginterferon beta-1aCytochrome P450 1A2enzyme
Human interferon betaCytochrome P450 1A2enzyme
Human interferon betaInterferon alpha/beta receptor 1target
Human interferon betaSerum albumincarrier
Interferon alfa-2cCytochrome P450 1A2enzyme